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Mechanistic Insights and
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HCM is a prevalent and complex disease
governed by multiple molecular mecha-
nisms, and there is currently no efficient
cure. New treatment strategies are
under development, and several drugs
are reaching the final stages of clinical
trials, with partial efficacy.
HCM disease models vary in complex-
ity. Furthermore, they are limited by
sample availability, demanding logistics,
preparation artefacts, oversimplicity,
and species-differences relative to
the human cardiovascular physiology,
often producing conflicting results.Hypertrophic cardiomyopathy (HCM) is a prevalent and complex cardiovascular
disease where cardiac dysfunction often associates with mutations in sarcomeric
genes. Various models based on tissue explants, isolated cardiomyocytes,
skinned myofibrils, and purified actin/myosin preparations have uncovered
disease hallmarks, enabling the development of putative therapeutics, with
some reaching clinical trials. Newly developed human pluripotent stem cell
(hPSC)-based models could be complementary by overcoming some of the in-
consistencies of earlier systems, whilst challenging and/or clarifying previous
findings. In this article we compare recent progress in unveiling multiple HCM
mechanisms in different models, highlighting similarities and discrepancies. We
explore how insight is facilitating the design of new HCM therapeutics, including
those that regulate metabolism, contraction and heart rhythm, providing a
future perspective for treatment of HCM.Application of genome-editing tech-
nology to hPSCs enables unlimited iso-
genic sets of heart cells in which the
primary mutation is the only change,
allowing elucidation of disease pheno-
types and genetic causation.
Uncovering new disease mechanisms
and targets will pave the way to more
efficient HCM therapeutics.
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(D. Mosqueira).HCM: A Complex Heart Disease
Cardiomyopathies constitute a heterogeneous group of diseases that represent the major
cause of heart failure (HF), and are defined by structural or functional perturbations of the
myocardium [1]. HCM is the most prevalent cardiac genetic disease, often leading to
sudden cardiac death at a young age [2]. Although described by increased left ventricle
(LV) wall thickness in the absence of abnormal loading conditions (see Clinician’s Corner),
HCM shares many hallmarks with other cardiomyopathies [3] and progresses to a compen-
satory phase. However, a sustained hypertrophic response leads to HF as a result of energy
and functional imbalance [4]. Although classically associated with preserved to hyper-
dynamic ejection fraction (EF), burn-out HCM with systolic dysfunction is also part of the
HCM spectrum [1].
Approximately half of HCM patients bear mutations in one or more of N20 genes encoding sarco-
meric proteins and associated myofilament elements that are responsible for regulating cardio-
myocyte contraction and ultimately cardiac function [5–7]. However, genetic causation is very
complex because HCM typically shows variable penetrance (see Glossary) and expressivity,
even in the same family [8] (Figure 1). This implies that factors beyond the single pathogenic mu-
tation (e.g., genetic/epigenetic background, environmental modifiers) influence the phenotype, as
verified in nonfamilial HCM patients [9].
Overall, the clinical and genetic complexity of HCM and its manifold molecular mechanisms
have hindered the development of effective treatment options. Although noninvasive monitoring
of cardiac function in patients has generated diagnostic tools for determining the progres-
sion of HCM [10], this approach cannot characterize disease mechanisms. Such under-Trends in Molecular Medicine, Month 2019, Vol. xx, No. xx https://doi.org/10.1016/j.molmed.2019.06.005 1
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Glossary
Cardiac troponin I/T (cTnI/T): cardiac
regulatory sarcomeric proteins that
control the calcium-mediated interaction
between actin and myosin.
CRISPR/Cas9: genome-editing
technology that enables the introduction
or correction of SNPs, for example in
sarcomeric genes involved in HCM. The
technology facilitates the generation of
isogenic sets of cardiac cells for disease
modeling.
Expressivity: the severity of the
phenotype that develops in a patient
with a pathogenic mutation.
Heterologous expression:
expressing a gene in a host organism
that normally does not produce it, by
recombinant DNA technology.
Human pluripotent stem cells
(hPSCs): these encompass (i) human
embryonic stem cells (hESCs) isolated
from the preimplantation blastocyst
stage embryo, and (ii) human induced
pluripotent stem cells (hiPSCs)
reprogrammed from somatic cells
donated by HCM patients and healthy
individuals.
Isogenic sets: cell lines that differ only in
the mutation being studied and retain the
same genetic background. This allows
the effect of the mutation in the disease
progression to be isolated (providing a
clearer understanding of genetic
causation) by directly comparing healthy
versus diseased isogenic counterparts.
Myosin-binding protein C (MYBPC):
a sarcomeric protein involved in
regulating the positions of myosin and
actin for interaction, acting as a brake on
cardiac contraction.
Myosin heavy chain (MHC): one of
the several sarcomeric proteins involved
in regulating cardiomyocyte contraction.
Can be expressed in two isoforms, α
and β, that are encoded by the MYH6
and MYH7 genes, respectively. Species
differences underlie changes in
compartmental expression of α- versus
β-MHC expression in the heart (β is the
main form expressed in human
ventricles)
Myosin light chain 2 (MLC2): also
known as regulatory light chain of
myosin, MLC2 is a sarcomeric protein
involved in modulating cardiac myosin
cross-bridge kinetics (its
phosphorylation enhances myofilament
sensitivity to calcium).
Penetrance: the proportion of
individuals carrying a pathogenic
mutation who display a phenotype.
Trends in Molecular Medicinestanding would allow progress towards better therapeutics. In this regard, several HCM
models that enable more refined analyses of cardiac physiology have been generated.
These include; (i) intact heart muscle strips, (ii) isolated cardiomyocytes, (iii) myofibrils de-
rived from skinned hearts, and (iv) purified actin/myosin sarcomeric proteins, as well
as (v) in silico approaches [11–13]. Although these models have contributed greatly to dis-
secting the hallmarks of HCM (the reader is directed to [14] for an exhaustive analysis), they
still pose several challenges such as sample availability, preparation artefacts, and species
differences (Figure 2, Key Figure). The recent application of genome editing to human
pluripotent stem cell (hPSC)-derived cardiomyocytes (hPSC-CMs) has enabled multi-
faceted investigation of the genetic causation of HCM, complementing previous models
(comprehensively reviewed in [15,16]).
In the following, we evaluate the pros and cons of different HCM models, and critically explore
recently uncovered discrepancies obtained from their study, to consolidate current knowledge
of disease mechanisms with a view towards future therapeutics.
Key Lessons from Heart Muscle Derivatives
Initial studies to dissect the mechanisms underlying HF were performed in cardiac muscle strips
from explanted human hearts [17], unveiling hallmarks of HCM. Post-mortem histological analysis
of cardiac tissue revealed extensive areas of interstitial fibrosis, myocyte enlargement, and chaotic
spatial arrangement in HCM patients [18]. Further investigations showed 2–2.5-fold increased
polyploidy in HCM, with inconsistent changes in multinucleation [19–21]. Isolated mitochondria
from human hypertrophied hearts exhibited about twofold higher oxygen consumption relative
to healthy controls [22].
Preservation of an intact sarcolemma in whole tissue preparations is advantageous for the re-
capitulation of cardiac tissue architecture and pharmacology in vitro. This led to characteriza-
tion of HCM pathophysiology by the identification of abnormal drug responses, including an
attenuated increase in contraction force induced by β-adrenergic agonists [23], and perturbed
calcium handling leading to prolonged relaxation during diastole [24]. However, cardiac tissue
biopsies are often derived from HF patients who have undergone myectomy to reduce muscle
thickening, and therefore require demanding logistics of sample handling (e.g., immediate
processing).
Mechanical and enzymatic dissociation of human endocardial tissue generates viable
cardiomyocytes that have been used for electrophysiology studies and pharmacological
responses [25], revealing arrhythmias (sixfold higher early after-depolarizations) and ~50%
higher diastolic Ca2+ concentrations. Single-cell transcriptome investigations revealed highly
variable mutant versus wild-type (WT) sarcomeric gene expression in heterozygous HCM
patients, underlying heterogeneous cell contractility and Ca2+ sensitivity [26].
However, isolated human cardiomyocytes dedifferentiate almost immediately after explant and
do not proliferate in culture [27]. Thus, human cardiac tissue and its derivatives offer an important,
but rarely available, biological source, and this greatly reduces the scope of the physiological
parameters that can be investigated.
Myofibrils from Skinned Heart Tissue/Cells: Direct Myofilament Evaluation
Subcellular structures have also been used to model HCM by placing tissue/cell-derived
skinned myofibril preparations between a force transducer and length motor, and immers-
ing in solutions with different Ca2+ concentrations to stimulate contraction/relaxation [28].2 Trends in Molecular Medicine, Month 2019, Vol. xx, No. xx
Sarcomeric mutation-negative
(SMN): HCM patients who do not
exhibit known mutations in sarcomeric
genes, constituting approximately 50%
of all cases.
Single-nucleotide polymorphisms
(SNPs): point mutations that cause a
change in the DNA sequence leading to
abnormal or truncated proteins with
perturbed structure and function, a
common cause of HCM.
Trends in Molecular MedicineThis method enables direct access to myofilament function to quantify isometric tension,
Ca2+ sensitivity, and ATP consumption (Figure 2). Most reports using this methodology
show decreased contractile force in human HCM samples. For instance, cardiac explants
from patients bearing different mutations in MYH7 and MYBPC3 genes [encoding β‐myosin
heavy chain (β-MHC), andmyosin-binding protein C, respectively] have consistently revealed
lower tension forces relative to healthy controls (21 vs 36 kN/m2), with MYH7-mutant samples
showing the lowest values when normalized tomyofibril density (73 vs 113 kN/m2) [29]. In addition,
Kraft et al. showed a modest increase in Ca2+ sensitivity of skinned myofibers from human cardiac
explants bearing the R723G-β-MHCmutation, relative to healthy controls, that was dependent on
the hyperphosphorylation state of several sarcomeric proteins [cardiac troponin I/T (cTnI/T),
MYBPC, andmyosin light chain 2 (MLC2] [30].
Simultaneous measurement of force development and ATPase activity in tissue-extracted
myofibrils can be used to quantify the energy cost of contraction. This revealed significant
increases for tissues from MYBPC3-mutant and MYH7-mutant patients, compared with
sarcomere mutation-negative (SMN) HCM patients, at saturating Ca2+ concentrations
[31]. This was corroborated in multicellular cardiac myofibrils of human R403Q-β-MHC, showing
~50% lower tension generation relative to SMN-HCM patients, as well as maximum ATPase
activity [32]. This results in a higher cost of contraction, indicating inefficient ATP utilization that
causes higher cardiac workload, often leading to HF (termed the ‘energy depletion model’ [4]).Trends in Molecular Medicine
Figure 1. Main Features of Hypertrophic Cardiomyopathy (HCM) Pathophysiology, Genetic Causation, Disease Progression, and Diagnosis. The
plethora of disease features and compensatory responses underlying HCM, as well as the overlap with other cardiomyopathies, make HCM a very complex condition
to diagnose and treat. Abbreviation: LV, left ventricle.
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Key Figure
Disease Models Used to Investigate Hypertrophic Cardiomyopathy (HCM) Phenotypes
Trends in Molecular Medicine
Figure 2. Although they offer different advantages, disadvantages, and outputs, recapitulating HCM physiology and complexity at varying degrees, disease models have
collectively enabled a deeper molecular understanding of disease progression, paving the way for its treatment. Abbreviations: CM, cardiomyocyte; EHT, engineered heart
tissue; hPSC, human pluripotent stem cell.
Trends in Molecular MedicineHowever, this difference was not observed in single myofibrils derived from the same tissues,
indicating that sample preparation affects the endpoint assay [33].
Nevertheless, myofibrils derived from skinned cardiac muscle offer simpler handling logistics
because samples can be frozen in a relaxation solution that preserves their functionality for several
months. Remarkably, higher energy cost in HCMmuscle strips appears to be a feature shared by
different mutations. This was recently corroborated in homozygous K280N-troponin T samples,
which showed 24–72% higher values than three different control groups, that was ascribed to
faster cross-bridge detachment [34].
Purified Actin/Myosin Proteins: Sarcomeric Interactions
Addressing the low sample availability limitations of whole-cell/tissue preparations, in vitromotility
assays were developed by recording the movement of fluorescently labeled actin filaments over a
layer of randomly oriented myosin molecules immunoadsorbed to an antibody-coated surface
[35]. Tethering an ultracompliant microneedle to actin filaments enables measurement of average
force per crossbridge, facilitating direct assessment of sarcomeric mutations and interactions at
the molecular level.4 Trends in Molecular Medicine, Month 2019, Vol. xx, No. xx
Trends in Molecular MedicineHowever, studies performed using this technique have produced results conflicting with whole-
tissue/cell analysis. For instance, rat tissues with heterologous expression of R403Q-α-MHC
showed a fourfold decrease in ATPase activity and a fivefold reduction in motility compared
with controls [36], whereas the same mutation in myosin isolated from mouse explants led to
2.3-fold higher ATPase activity and 60% higher velocity than WT myosin tissue [37]. These
discrepancies extended to human biopsies. Although tissues from patients harboring β-MHC
mutations displayed consistently lower sliding velocities (0.11–0.29 μm/s) than healthy controls
(0.48 μm/s) [38], another report showed the opposite in R403Q- and L908V-βMHC, which had
30% higher velocities [39].
These differences highlight the main drawback of this method: technical artefacts derived
from protein purification procedures. Tissue biopsies contain limited concentrations of
myosins that are further degraded by freezing and tissue handling procedures. Alternatively,
heterologous production of recombinant proteins often result in changes in structure and
expression levels relative to endogenous systems, with functional consequences for the
endpoint assay [14].
These limitations are evidenced when analyzing the same protein interactions by different
techniques. Laser-trap assays can be used for direct molecular analysis of actin–myosin interac-
tions by measuring the force and displacement resulting from the interaction of a single myosin
molecule with an optically trapped actin filament [40]. The same group has shown significant
differences between myosin extracted from mice bearing the R403Q-β-MHC mutation vs WT
when performing in vitro motility assays (2.3-fold higher ATPase activity, 2.2-fold greater force
generation, and 1.6-fold faster actin filament sliding), but no changes in force and displacement
in the same samples when using the optical trap assay [37].
Taken together, these differences suggest that more reductionist models, where isolated
proteins are investigated under unloaded conditions, tend to generate less robust conclusions
due to technical constraints and the absence of physiological complexity that is characteristic of
highly organized sarcomeres.
Animal Models: Transgenics and Species Differences
Animal models of heart disease have been crucial in advancing knowledge of pathophysiology
towards new therapeutics because the basic principles of cardiac excitation and contraction in
the species used are relatively conserved [41]. Although some naturally occurring cardiomyopa-
thies have been detected in animals (e.g., Portuguese waterdogs), transgenic animal models
enable detailed physiological and molecular analysis of disease [11,42]. Rodents (e.g., Syrian
hamsters [43]) in particular have been extensively employed to model HCM because they over-
come cell source limitations and facilitate whole-organism investigation of disease progression
over time.
Primary cardiomyocytes isolated from transgenic rats and mice have been integrated into
fibrin-based engineered heart tissues (EHTs) that enable assessment of contractility by
measuring the displacement of silicon posts to which they are attached [44]. Analysis of
the contractile force of rat cardiomyocytes transduced with adeno-associated virus expressing
FLH1 variants containing single-nucleotide polymorphisms (SNPs) identified in HCM
patients revealed hyper- or hypocontractile phenotypes depending on the mutation
(K455fs-Fhl1, 27% higher force; C276S-Fhl1, 23% lower force vs WT controls). Evaluation
of the beating kinetics of these tissues showed prolonged contraction and relaxation
times in both variants (~18% and ~30% longer, respectively) [45]. The same approachTrends in Molecular Medicine, Month 2019, Vol. xx, No. xx 5
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and relaxation velocities in T123M-Ankrd1 EHTs versus controls, but no discernible pheno-
types in P52A and I280V variants [46]. This reinforces the notion that HCM phenotypes
are mutation-specific because different mutations in the same locus elicit variable effects
on contraction.
Furthermore, data from transgenic mouse models have clearly linked mutations in sarcomeric
genes with impaired Ca2+ handling. Knollmann and colleagues studied isolated cardiomyocytes,
perfused hearts, and whole mice bearing the human I79N-cTnT mutation, showing shortened
ventricular action potentials at 70% repolarization (14 ms in I79N-cTnT, vs 23 ms in control).
Ca2+ transients of electrically stimulated ventricular I79N-cTnT myocytes were measured
using a fluorescent Ca2+ indicator dye (Fura-2-AM) and showed reduced intensity (half the
fluorescent amplitude in I79N-cTnT vs control) and twofold slower decay kinetics, consistent
with increased Ca2+ sensitivity of I79N-cTnT mutant fibers [47]. Moreover, EHTs made from
Mybpc3-mutant mice displayed higher sensitivity to Ca2+, as evidenced by lower Ca2+ EC50
values for force generation relative to the WT (0.34 mM for homozygous, 0.48 mM for hetero-
zygous, vs 0.66 mM for WT) [48,49]. This methodology has also shown differences in Ca2+
EC50 values for contraction between species (0.15, 0.39, and 1.05 mM Ca
2+ for rat, mouse,
and human EHTs, respectively [50]).
The variation in Ca2+ EC50 values for contraction between species highlights the main
drawback of animal models – the existence of striking dissimilarities in cardiovascular
physiology relative to humans. These are particularly prominent in the mouse: mice have
~10-fold faster beat rates (500 bpm vs 60 bpm) and 5–10-fold shorter electrocardiogram
duration (50–100 ms vs 450 ms) relative to humans [41]. Changes in gene expression
are also abundant, such as those pertaining to α/β-MHC expression: whereas in humans
the α isoform is mainly located to the atria and the β to the ventricles [51], in the mouse
the α-MHC is highly expressed in both compartments [52]. Despite sharing N90% se-
quence homology, this discrepancy in α versus β-MHC expression is reflected in the animal
models generated.
Knock-in R403Q-α-MHC mice exhibited a significant enhancement in ATPase activity and
transient kinetics (e.g., 20% increase in ADP release rate) relative to WT littermates, whereas
R403Q-β-MHC animals displayed opposite or nonsignificant changes [53,54]. These inconsis-
tencies are further exacerbated when comparing the samemutation in different animals. A recent
report characterizing a transgenic rabbit model of the same mutation R403Q-β-MHC showed
~20% lower force generation in comparison with WT littermates in single myofibril analysis by
atomic force microscopy [55], whereas transgenic mouse models show the opposite in actin–
myosin assays [37]. These incongruities between models make it challenging to translate these
findings to the human disease phenotype.
hPSC-CMs: An Unlimited Cell Source
Addressing the limitations of previous samples, hPSC-CMs have been harnessed for disease
modeling because they constitute an unlimited cell source [56] that enables multiparametric
and detailed studies in patient-relevant genomes (Figure 2). Cardiac differentiation protocols
recapitulating heart development can be applied to hPSCs, thereby generating highly pure
cardiomyocyte populations [57] (Box 1). To interrogate different features of HCM pathology in
hPSC-CMs, several medium- and high-throughput phenotypic assays that measure cardiomyo-
cyte structure, metabolism, electrophysiology, calcium handling, and contractility have been de-
veloped [58,59].6 Trends in Molecular Medicine, Month 2019, Vol. xx, No. xx
Box 1. Methods for Differentiating hPSCs into Cardiomyocytes
To generate LV hPSC-CMs needed for modeling HCM, several protocols were developed based on recapitulation of car-
diac development. hPSCs undergo sequential differentiation steps (mesoderm, cardiac mesoderm, cardiac progenitors)
that are spatiotemporally regulated by different growth factor combinations to form cardiomyocytes [118]. These protocols
can generally be divided into four main classes: (i) inductive coculture, (ii) embryoid body (EB) formation, (iii) monolayer
culture, and (iv) suspension culture [57].
Early differentiation protocols relied on coculture of hPSCs with a murine visceral endoderm-like cell line (END-2) which
provided the growth factors [activin A, bone morphogenetic protein (BMP)] necessary to control cardiogenesis
[119,120]. Although coculture requires few cells, it is a time-consuming and labor-intensive method that results in impure
cardiomyocyte populations surrounded by a murine cell line, rendering this protocol unsuitable for HCM modeling.
Methods for generating EBs are based on suspension cultures of hPSCs as single cells or small clumps in a medium that
drives cardiogenesis. EBs can be formed in many ways, allowing variable control of EB size and number (e.g., in ultra-low
attachment static conditions, hanging-dropmethod, and forced aggregation in V-shaped wells). Despite being successful,
these methods are not amenable to scale-up and require very strict control of parameters such as the initial number of
cells, resulting in heterogeneous cell types. EB cardiomyocytes often do not survive the dissociation into single cells that
is required for phenotypic analyses [57].
Unlike EBmethods where complex diffusional barriers confound the concentration of growth factors hPSCs are exposed to,
uniform monolayer 2D cultures provide a more controlled and reproducible differentiation environment. Additional
improvements such as temporal exclusion of insulin from the medium and/or the incorporation of a Matrigel™ overlay step
resulted in higher cardiomyocyte purities (~90%). To decrease the variability and costs associated with growth factor-based
protocols, several small molecules have been explored for driving cardiac differentiation, such as GSK3β inhibitor ChiR and
the WNT inhibitors IWR-1-4, KY0211, and XAV939, resulting in cost-effective production of cardiomyocytes [121–123].
Although cardiac monolayer protocols typically result in high numbers of hPSC-CMs, cardiomyocytes suffer inherent
heterogeneity (mixed subtype populations), batch variation, limited scalability, and interlaboratory variability [124] because
small-scale 2D cultures are sensitive to fluctuations in physicochemical parameters. To greatly increase the scalability
of differentiation protocols, several 3D suspension bioreactor systems have produced CMs from hPSCs by using
anchorage-dependent (i.e., microcarrier-based) and -independent systems [125–127]. These recent protocols produce
high purities of abundant LV cardiomyocytes that are essential for modeling HCM.
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pioneered the field by reporting in vitro phenotypes of R663H-β-MHC cardiomyocytes, namely
increased multinucleation (48.3%) relative to healthy controls (22.1%), with stark abnormalities in
calcium handling (about threefold higher percentage of cells displaying arrhythmias) [60]. Accord-
ingly, R442G-β-MHC hPSC-CMs exhibited irregular Ca2+ transients (20% of the cells vs virtually
none in healthy controls). Mutant cardiomyocytes showed a 21% increase in resting Ca2+ concen-
tration and 50% lower Ca2+ release from the sarcoplasmic reticulum (SR) upon caffeine treatment
relative toWT controls [61]. Tanaka et al. coupled high-speed videomicroscopy with amotion vec-
tor prediction algorithm to investigate myofibrillar disarray in hPSC-CMs derived from three HCM
patients, showing an increased percentage of cells exhibiting disorganized sarcomeres (~9%) rel-
ative to controls (~5%) [62]. Moreover, myofibrils derived from hPSC-CMs bearing the E848G-β-
MHC mutation showed ~56% lower maximal isometric tension forces relative to controls, with
faster kinetics of actin–myosin cross-bridge detachment [63]. Finally, R58Q-MYL2 hPSC-CMs re-
cently reported significantly lower ICa,L current density relative to a control line, which led to irregular
beating, suggesting impaired diastolic relaxation [64].
However, although hPSC-CMs enable detailed studies at the molecular, myofibrillar, cellular, and
tissue levels (when integrated into EHTs), they are immature in comparison to adult CMs, with
differences ranging from morphological and gene expression up to structural and functional
properties [65], namely an absence of T tubules [66]. This was evidenced in [67] where induced
pluripotent stem cell (iPSC)-derived CMs (iPSC-CMs) bearing truncating mutations in TTN
displayed striking hypocontractility, TTN haploinsufficiency, and decreased sarcomere length,
which were not observed in adult myofibril samples.lecular Medicine, Month 2019, Vol. xx, No. xx 7
Trends in Molecular MedicineMoreover, hPSC-CM disease models fail to recapitulate the physiological complexity of a multi-
cellular intact heart system that encompasses fluid dynamics inherent to the circulatory system
as well as neurohormonal control (i.e., metabolic changes) and extracellular matrix alterations
(e.g., fibrosis). Recent efforts have included additional cell types such as cardiac fibroblasts or en-
dothelial cells, although these were derived from different sources with multiple genetic back-
grounds [68]. Thus, HCM modeling studies using hPSC-CMs should also be interpreted
carefully because hallmarks of disease may be under- or overestimated [16]. Nevertheless,
these cells offer a direct approach to address the highly complex genetic causation of HCM.
Isogenic Sets to Comprehend Genetic Causation
A limitation of earlier studies employing hPSC-CMs was that the impact of (epi)genetic back-
ground on phenotype can exceed that caused by the pathogenic mutation, as evidenced by var-
iations in action potential durations between 100–700 ms among different lines described as
‘healthy controls’ [69]. This was also verified in patients, as recently reported for monozygotic
twins carrying the same mutation (G768-β-MHC) but showing differences in myocardial fibrosis
[70].
Gene-editing technologies such as CRISPR/Cas9 enable the generation of isogenic sets
wherein precise changes can be made to the genome in an otherwise constant genetic back-
ground. Changes can range from large insertions or deletions (e.g., the ~65 kb Dip2a gene
[71]) to single bases leading to point mutations [72,73]. This means that, by coupling hPSCs
with genome-editing technology, sets of disease-related and healthy isogenic hPSC-CMs can
be compared to isolate the effect of the mutation on disease progression [74].
This ‘isogenic’ strategy has only very recently been used to model HCM. Isogenic sets of R302Q-
PRKAG2 versus CRISPR-corrected hPSC-CMs were used to evaluate beating parameters by
microelectrode array analysis [75]. This model identified arrhythmogenic events in diseased
hPSC-CMs which were abolished upon CRISPR-mediated correction. Beat rate variability was
much higher in diseased lines (coefficient of variation ~30%), although there were differences be-
tween the two healthy controls (unrelated ~5% vs CRISPR-corrected ~12%), reinforcing the need
for isogenic sets.
Genome editing enables a wider range of genotypes to be generated. This was explored in
[76], wherein hPSCs from an asymptomatic patient carrying a heterozygous A57N-MYL3
mutation were further engineered to generate WT (corrected), homozygous mutant, and
heterozygous frameshift mutant. Despite analyzing several parameters (morphology, tran-
scriptome, sarcomeric structure, contractility, action potentials, and calcium handling), none
of these lines exhibited a phenotype, unlike another known heterozygous pathogenic muta-
tion (A57G-MYL3).
Wang et al. characterized isogenic sets of I79N-cTnT hPSC-CMs, and these recapitulated
the phenotypes described in the transgenic mouse model bearing the same mutation
{hypercontractility, impaired relaxation, increased Ca2+ sensitivity, and pro-arrhythmic de-
creased action potential (AP) duration [77]}. The reduced systolic Ca2+ release upon caffeine
addition is likely to be due to calcium buffering by the calcium-sensitive mutant cTnT because
treatment with calcium sensitizer, EMD57033, precipitates AP instability and arrhythmias in
both models.
Smith et al. generated isogenic sets of E99K-ACTC1 variants, either by correcting or inserting the
mutation in patient-derived hPSCs [78]. Notably, inserting the E99K-ACTC1 mutation in healthy8 Trends in Molecular Medicine, Month 2019, Vol. xx, No. xx
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(3.6-fold higher contraction force in EHTs, increased Ca2+ sensitivity, and double the prevalence
of arrhythmogenic events). Genomic correction of the diseased line restored the abnormalities
back to baseline levels, which renders this mutation as ‘necessary but not sufficient’ to cause
HCM. These results are in line with studies on a previous transgenic mouse model [79,80]
which also reported enlarged atria and increased interstitial fibrosis. However, it is likely that the
noncardiomyocyte cell types and full embryonic development that are absent from the hPSC-
CM model play an important role in developing HCM phenotypes. Nevertheless, isogenic sets
allowed a deeper understanding of the genetic causation of the disease by suggesting that back-
ground (epi)genetics acts as an important modulator of the pathogenic phenotype.
Engineering the samemutation in several hPSC lines and analyzing disease phenotypes facilitates
direct evaluation of its penetrance. This approach was explored by CRISPR/Cas9-mediated
engineering of the R453C-β-MHC change in three independent hPSC lines, generating 11 different
genetic variants in total (entailing heterozygous, homozygous, homozygous plus α-MHC frame-
shift, and knockout genotypes) [81]. Extensive molecular and functional evaluation of hPSC-CMs
showed recapitulation of the main hallmarks of HCM in all three isogenic sets, with differences in
magnitude that were correlated with the mutant:WT allele expression ratio in the heterozygous
lines. In the most diseased line (~60% mutant:WT allele expression), hypertrophy (51% increase
in cell volume), sarcomeric disarray, increased mitochondrial respiration, arrhythmias, and
hypocontractility (16.3–81.3% lower force) were reported. The mutation load was associated
with the level of phenotypic perturbation, and the energy-depletion phenotype likely hampers the
energetically demanding SERCA2a pump, resulting in higher levels of intracellular Ca2+, leading
in turn to increased risk of arrhythmia. This human model corroborated energy depletion as an
underlying response to HCM mutations [4,22].
Unveiling HCM Complexity: Hypercontractility versus Hypocontractility
Contraction changes reported in R453C-βMHC hPSC-CMs are opposite to the response
previously reported in transgenic mouse models, which showed 80% higher force in homozy-
gous mutant cardiac myosins [82] and ~50% increase in maximal force in heterologous mouse
cells [83] (Table 1). However, the hPSC-CM data are consistent with isometric tension analysis
from explanted human HCM tissue [29] and E848-βMHC hPSC-CMs [84]. This discrepancy is
probably due to species differences between mouse and human hearts, namely pertaining to
the ventricular predominance of α versus β-MHC expression [51,52].
Accordingly, a recent review compiled all the data from human skinned muscle strips, isolated
cardiomyocytes, and myofibrils obtained from frozen HCM hearts bearing mutations in the
MYBPC3, MYH7, TPM1, TNNT2, or TNNI3 sarcomeric genes. Across the 15 studies reviewed,
spanning tens of gene–mutation combinations, maximal force developed by cardiomyocytes
averaged ~40% lower than control hearts in almost all cases [85].
Arguably, hypo- versus hypercontractile effects are mutation-specific, accounting for the highly
complex genetic causation of HCM, which often shows overlapping features with other
cardiomyopathy forms such as dilated cardiomyopathy, thwarting understanding of disease
progression [86].
A hypocontractile phenotype in HCM can be clinically explained by the concentric nature of the
hypertrophy: thickening of the ventricular walls without increase in heart size leads to a smaller
LV end-diastolic volume. This causes an apparent hypercontraction [resulting in similar or higher
LV ejection fraction, (LVEF)] but not when normalized to cardiomyocyte or myofibril densityTrends in Molecular Medicine, Month 2019, Vol. xx, No. xx 9
Table 1. Discrepancies in HCM Characterization between Different Models
Model Species System Mutation Assay Result (vs control)a Refs
Purified actomyosin Rat Heterologous expression R403Q-αMHC In vitro motility ↓ ATPase activity (fourfold)
↓ Motility (fivefold)
[36]
Purified actomyosin Mouse Transgenic tissue explant R403Q-αMHC In vitro motility ↑ ATPase activity (2.3-fold)
↑ Motility (60%)
[37]
Purified actomyosin Human Tissue explant R403Q-βMHC In vitro motility ↓ Sliding velocity (73%) [38]
Purified actomyosin Human Tissue explant R403Q-βMHC In vitro motility ↑ Sliding velocity (30%) [39]
Purified actomyosin Mouse Transgenic tissue explant R403Q-βMHC In vitro motility ↑ ATPase activity (2.3-fold)
↑ Force generation (2.2-fold)
↑ Sliding velocity (1.6-fold)
[37]
Purified actomyosin Mouse Transgenic model R403Q-αMHC
(homozygous)
Laser trap ↑ Force generation (50%)
↑ Sliding velocity (24%)
[82]
Purified actomyosin Mouse Transgenic tissue explant R403Q-βMHC Laser trap = Force generation [37]
Purified actomyosin Rabbit Transgenic model R403Q-βMHC In vitro motility = ATPase activity
↓ Sliding velocity (50%)
[55]
Single myofibril analysis Rabbit Transgenic model R403Q-βMHC Atomic force microscopy ↓ Force generation (17%) [55]
Multicellular myofibril analysis Human Tissue explant R403Q-βMHC Tension (force/area) ↓ Tension generation (53%) [32]
Purified actomyosin Mouse Transgenic model R453C-αMHC
(homozygous)
Laser trap ↑ Force generation (80%)
= Sliding velocity
[82]
Purified actomyosin Mouse Cell line heterologous
expression
R453C-βMHC In vitro motility ↓ ATPase activity (30%)
↑ Force generation (50%)
[83]
hPSC-CM-EHTs Human hPSC-CMs R453C-βMHC EHT (contractile force) ↓ Force generation (16–81%) [81]
aKey: ↓, decreased; ↑, increased; =, no change.
Trends in Molecular Medicine[87,88]. Interestingly, echo-based strain imaging has consistently reported hypocontractile
function in HCM patients [89].
These findings question the reliability of over-simplistic assays of surrogate measurements of
contractility solely based on the interaction of two myofilament proteins. They also question the
physiological relevance of at least somemurine models which are known to have striking species
differences relative to humans [52]. In others, such as mouse and human muscle fibers bearing
the F764L-MYBPC3 HCM mutation, a hypercontractile phenotype was consistently reported in
both [90]. Notwithstanding, whole-organism in vivo models do not simply reflect situations
in vitro. Importantly, it is conceivable that variations in contractile force in HCM change with
disease course, in other words it may be hyperdynamic early (compensatory phase) but
hypocontractile later (end-stage).
Pharmacological Intervention Strategies for Treating HCM
Disease models that recapitulate HCM phenotypes offer a powerful platform for screening phar-
macological rescue strategies. However, the varied phenotypes and molecular mechanisms
associated with different HCM-associated mutations prevent a consensus on the most efficient
treatment strategies. Thus, pharmacological interventions with diverse modes of actions can be
effective in HCM rescue (Figure 3). Treatments include β-blockers, L-type Ca2+ channel blockers,
antiarrhythmic drugs, calcium desensitizers, and metabolic and contractility modulators [91,92].
β-Blockers were first used to treat symptomatic HCM in the 1960s [93] because, by modulating
heart rate, ventricular contractility, and stiffness, they can improve ventricular relaxation in HCM
patients [94,95]. A range of β-blockers have been used, including propranolol and metipranolol,10 Trends in Molecular Medicine, Month 2019, Vol. xx, No. xx
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Figure 3. Ongoing Pharmacological Strategies to Treat Hypertrophic Cardiomyopathy (HCM). Disease models have uncovered several molecular players in
cardiomyocytes that can be targeted by drugs (in red). β-Blockers prevent adrenergic signaling, leading to reduced heart rate and improved ventricular relaxation.
Drugs targeting LTCC, RYR2, and NCX reduce the intracellular calcium build-up that underlies arrhythmogenic events associated with HCM. Metabolic modulators
such as perhexiline and trimetazidine inhibit fatty acid oxidation, thereby promoting the use of glucose as an energy substrate and fostering improved energy efficiency
by reversing the energy depletion phenotype. Blebbistatin and epigallocatechin-3-gallate (EGCG) alter myofilament calcium sensitivity. Mevacamten reduces
contractility by decreasing the ATPase activity of sarcomeric myosin heavy chain. Omecamtiv mecarbil increases actin–myosin binding, which results in enhanced
cardiomyocyte contraction. Abbreviations: β-AR, β-adrenoreceptor; FA, fatty acid; LTCC, L-type calcium channel; NCX, sodium/calcium exchange pump; SR,
sarcoplasmic reticulum; RYR2, ryanodine receptor.
Trends in Molecular Medicinebut it remains unclear why some are more effective than others [96]. Patient specific hPSC-CMs
have demonstrated their efficacy: metoprolol significantly decreased beating irregularity and
arrhythmias in an R442G-β-MHC model [61].
Elevated intracellular Ca2+ and dysfunctional Ca2+ cycling are commonly reported to be
central to the pathogenesis of HCM, and inhibition of Ca2+ entry by L-type Ca2+ channel
blockers has been investigated for the treatment of HCM [97]. In a hPSC-CM model of
R663H-β-MHC mutation, diltiazem abolished calcium-handling abnormalities and arrhyth-
mias, whereas verapamil also prevented myocyte hypertrophy, fully alleviating the HCM
phenotype [60]. Another Ca2+ blocker, nifedipine, reduced arrhythmia in R453C-β-MHC
hPSC-CMs [81].
Intracellular Ca2+ levels can be targeted indirectly through antiarrhythmic drugs that inhibit Na+
influx, such as mexiletine and ranolazine [98]. These reduce intracellular Ca2+ by targeting the
Na+/Ca2+ exchanger and promoting Ca2+ efflux to restore intracellular Na+ levels. Ranolazine halved
the number of arrhythmias in R453C-β-MHC hPSC-CMs [81] and reduced hypertrophic brain
natriuretic peptide (BNP) signaling in E99K-ACTC1 hPSC-CMs [78]. Hypertrophic signaling was re-
duced further in combination with dantrolene, a drug that blocks SR Ca2+ release through inhibitingTrends in Molecular Medicine, Month 2019, Vol. xx, No. xx 11
Clinician’s Corner
HCM is a prevalent and complex
cardiomyopathy that often leads to heart
failure when cardiac function is unable to
meet the metabolic requirements of the
body [1]. HCM is defined by thickening
of the left ventricle (LV) that is associated
with preserved to increased ejection
fraction [1]. Diagnosis of HCM relies on
detection of increased LV wall thickness
by several imaging technologies as well
as by genetic screening [1,97].
HCM exhibits intricate genetic causation:
its effects are mutation-specific, and clini-
cal outcomes range from asymptomatic
to sudden cardiac death [115–117].
There is no current effective treatment
for HCM, and heart transplantation is
the only long-term solution [97].
Previous HCM models have highlighted
hallmarks of disease: hypertrophy,
perturbations in calcium handling
(arrhythmias), contractility, and energy
imbalance [3]. Gene-edited human
pluripotent stem cell-derived cardio-
myocytes enable more refined analysis
of the genetic causation of HCM and
multiparametric investigation of disease
mechanisms.
Developing better models of HCM will
enable deeper understanding of HCM
molecular mechanisms leading to
more efficient treatment options.
Trends in Molecular Medicinethe ryanodine receptor (RYR2) [78]. However, Phase II clinical trials (clinicaltrialsregister.eu
2011-004507-20) have not shown efficacy of ranolazine to improve functional capacity in
HCM [99]. This is possibly due to other organ-level features such as myocardial fibrosis that
may overrule the cellular effects or ranolazine, or to the high variability in late sodium current
expression in HCM cardiomyocytes [100].
An alternative therapeutic strategy for reducing intracellular Ca2+ is to target myofilament
Ca2+ sensitivity with desensitizing drugs. The myosin inhibitor blebbistatin alters myofilament
sensitivity via an inhibitory effect on actomyosin cross-bridge formation [101], and 3 μM
treatment prevented pro-arrhythmic AP triangulation in I79N-TnT hiPSC-CMs [77].
Epigallocatechin-3-gallate (EGCG) is a calcium desensitizer that acts through the formation
of a ternary complex with cTnC and cTnI [102]. EGCG treatment completely reversed
abnormal Ca2+ sensitivity analyzed by an in vitro motility assay of seven HCM-related muta-
tions in cTnT [103].
Energy depletion also has therapeutic potential in HCM. Metabolic modulators that shift the
substrate preference from fatty acids towards glucose are being increasingly investigated
[103] because they increase ATP production with the same oxygen consumption (thus
improving myocardial efficiency). Perhexiline promotes the use of carbohydrates as the
substrate for myocardial energy by inhibiting carnitine-palmitoyltransferase [104], increasing
exercise capacity in Phase II trials for HCM patients (ClinicalTrials.gov NCT00500552)
[105]. However, other metabolic modulators such as trimetazidine, a direct inhibitor of
fatty acid β-oxidation, have shown limited effectiveness in recent HCM clinical trials
(ClinicalTrials.gov NCT01696370) [106], although its use for preventive therapy is now
being investigated [107].
Because disease models have shown changes in contraction force, modulators of contractility
are under investigation. The allosteric modulator of cardiac myosin, mevacamten, reduces
contractility by decreasing the ATPase activity of cardiac MHC in a mouse model of HCM
[101], also showing effectiveness in reversing the hypercontactility seen in truncated
MYBPC hPSC-CM mutants [108]. Phase III clinical trials are now ongoing to test mevacamten
efficacy in adults with symptomatic obstructive HCM (ClinicalTrials.gov NCT03470545),
with completion expected in June 2020 [97]. Conversely, omecamtiv mecarbil (OM) is being
tested to treat hypocontractility in patients by augmenting the speed of ATP hydrolysis, thus
increasing myosin head binding to actin, which results in an enhanced force-producing
state [109]. Interestingly, the effects of OM are dependent on intracellular Ca2+ levels
(increasing contractility at low Ca2+ concentrations, and decreasing it at higher concentra-
tions [110]). Despite displaying limited effectiveness in R453C-β-MHC hPSC-CMs [81]
(possibly due to the inherent immaturity of these cells), OM has shown encouraging clinical
results, progressing to Phase III trials (ClinicalTrials.gov NCT02929329) that are due for
completion in January 2021 [111].
Altogether, data from earlier models revealed that HCM is governed by multiple pathways,
leading to progression of new drugs into clinical trials, although some are showing dis-
appointing efficacy. HCM disease models based on isogenic hPSC-CMs offer a high-
throughput system for investigating the relative efficacy of a range of combinatorial pharma-
cological interventions in diverse HCM genetic backgrounds. Data from such screening
projects may inform more effective and mutation-specific use of therapeutic drugs. These
studies highlight the importance of greater mechanistic understanding to facilitate therapeu-
tics for HCM.12 Trends in Molecular Medicine, Month 2019, Vol. xx, No. xx
Outstanding Questions
Refinement of disease models: the
heart comprises cardiomyocytes,
cardiac fibroblasts, smooth muscle
cells, and endothelial cells, with
additional neurohormonal control.
Therefore, what cell types should be
used to recapitulate HCM in vitro, and
in what proportions, while managing
the balance between practical use
and over-complexity? Are there proto-
cols to efficiently derive all these cell
types from hPSCs bearing HCMmuta-
tions? Will these cells integrate in func-
tional tissues?
How can the whole-tissue/organ inter-
stitial and perivascular fibrosis charac-
teristic of HCM be reproduced in vitro?
What is the best strategy to improve
maturation of hPSC-derived cardiac
cell types while maintaining compati-
bility with high-throughput pheno-
typic assays?
Less explored mechanisms of disease:
what is the contribution of autophagy
to HCM progression? What is the mo-
lecular mechanism linking telomere
shortening to HCM progression?
Is heart tissue polyploidy associated with
the compensatory response to HCM?
Is there an underlying/unifying phenotype
of HCM among patients with different
Trends in Molecular MedicineConcluding Remarks
HCM is an ‘umbrella’ term used to describe a tough-to-treat and very complex disease asso-
ciated with an intricate genetic causation. It exhibits a heterogeneous set of clinical manifestations
with a wide spectrum of molecular mechanisms.
Earlier disease models have greatly contributed to understanding HCM progression, and
have proved to be useful as a collective to advance treatment. However, they have often failed
to faithfully phenocopy HCM in vitro owing to its intricate and multifarious nature. Unlimited pro-
duction of hPSC-CMs has facilitated deeper mechanistic studies, complementing approaches
from previous models. Genome-edited isogenic cell models have enabled detailed investigation
of the genetic causation of HCM, and their further study is expected to unearth new gene
modifiers, mechanisms, and therapeutic opportunities (see Outstanding Questions).
Importantly, transcriptomic data are available and are expected to highlight newmolecular targets
for therapy. Two reports have performed RNA sequencing analysis from nongenetically profiled
patient-derived tissue explants, identifying hundreds of differentially expressed genes relative to
unrelated healthy controls [112,113]. Data on transcriptomic analysis of isogenic sets of HCM
hPSC-CM lines have recently been published [81,114] providing genetically precise comparisons
for identifying new molecular mechanisms of disease.
The unsatisfactory efficacy of drug management of HCM [96] is likely due to the use of suboptimal
preclinical testing carried out in physiologically irrelevant animals [56] and/or by lack of consideration
of the complex genotype–phenotype relationship characteristic of HCM. The development of
refined models of HCM will further elucidate this complex disease by recapitulating human adult
conditions of pathology. AlthoughHCM is primarily a condition of the cardiomyocytes, incorporating
multiple cardiac cell lines in in vitro models will improve in vivo pathophysiological relevance. Opti-
mizing technical constraints associated with human tissue explant analysis and solving the relative
immaturity of hPSC-CMs will also foster the generation of more sophisticated HCM models that
could accurately predict drug responses to treat this multifaceted disease.Acknowledgments
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